Vertex Pharmaceuticals (VRTX) Return on Capital Employed (2010 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Return on Capital Employed of 21.1% for Q1 2026, up 2503.0% year-over-year from 0.81% in Q1 2025, and up 8.17% quarter-over-quarter from 19.51% in Q4 2025.
Vertex Pharmaceuticals (VRTX) Return on Capital Employed (2010 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 21.1% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2503.0% year-over-year to 21.1%; the TTM figure through Mar 2026 stood at 21.1% (up 2503.0% YoY), while the FY2025 annual figure was 20.63%, up 2185.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 21.1%, up from 19.51% in the prior quarter.
- The five-year high for Return on Capital Employed was 33.0% in Q2 2022, with the low at 3.92% in Q1 2025.
- The 5-year median for Return on Capital Employed is 21.1% (2026), against an average of 17.94%.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed plunged 2620 bps in 2024, then soared 2503 bps in 2026.
- Vertex Pharmaceuticals' Return on Capital Employed stood at 29.33% in 2022, then tumbled by 30 bps to 20.51% in 2023, then slumped by 106 bps to 1.24% in 2024, then soared by 1677 bps to 19.51% in 2025, then increased by 8 bps to 21.1% in 2026.
- Business Quant data shows VRTX's Return on Capital Employed at 21.1% in Q1 2026, 19.51% in Q4 2025, and 19.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.76% |
| Mar 31, 2026 | 21.10% |
| Dec 31, 2025 | 19.51% |
| Sep 30, 2025 | 19.99% |
| Jun 30, 2025 | 20.31% |
| Mar 31, 2025 | -3.92% |
| Dec 31, 2024 | -1.24% |
| Sep 30, 2024 | -1.57% |
| Jun 30, 2024 | -1.89% |
| Mar 31, 2024 | 21.47% |
| Dec 31, 2023 | 20.51% |
| Sep 30, 2023 | 22.23% |
| Jun 30, 2023 | 24.31% |
| Mar 31, 2023 | 26.04% |
| Dec 31, 2022 | 29.33% |
| Sep 30, 2022 | 30.67% |
| Jun 30, 2022 | 33.00% |
| Mar 31, 2022 | 25.16% |
| Dec 31, 2021 | 25.56% |
| Sep 30, 2021 | 25.23% |